Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 million
Executive Summary
Russia's bid to catch up in the global race to establish a recognized biopharma sector picked up speed with the Aug. 4 announcement of SynBio, a $110 million joint venture to develop bio-betters and innovative medicines for the Russian and international markets.
You may also be interested in...
Rusnano Teams With Domain Associates To Co-Fund Life Sciences Companies And Establish Pharma JV In Russia
Russian sovereign fund is co-investing with Domain in the VC’s portfolio life sciences companies, and the pair also will fund a manufacturing facility in Russia.
Celtic Pharma And Russia's Rusnano Set Up Pro Bono Bio, A New Firm With Philanthropic Objectives
An Anglo-Russian company, Pro Bono Bio, launches new analgesic and will price its products according to ability to pay.
Celtic Pharma And Russia's Rusnano Set Up Pro Bono Bio, A New Firm With Philanthropic Objectives
An Anglo-Russian company, Pro Bono Bio, launches new analgesic and will price its products according to ability to pay.